top of page
Search

Lipid Nanoparticle (LNP) News Brief Summary (April 29 – May 12, 2025)



LNP 3d Image

Company News Summaries

Mana.bio: Presented new data demonstrating AI-driven safety model for lipid nanoparticle tolerability to enhance RNA medicine.


Grit Biotechnology: Presented scientific breakthroughs at ASGCT 2025 including LNP-mediated CRISPR/Cas9 gene editing for enhancing tumor-infiltrating lymphocytes.


Generation Bio: Reported business highlights including advancement of their cell-targeted lipid nanoparticle (ctLNP) technology for siRNA delivery.


Aera Therapeutics: Shifted focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein nanoparticles.


Serina Therapeutics: Secured $15 million in equity financing and presented data on their POZ-lipid for improved LNP formulations that showed no antibody response following repeat dosing.


Acuitas Therapeutics: Demonstrated enhanced mRNA-LNP activity in cancer and viral vaccine development, sharing key findings at the 2025 World Vaccine Congress.

Announced plans to present oral session and posters on successful repeated dosing of mRNA-LNP in monkeys at ASGCT 2025.


Various Pharmaceutical Companies: Global Lipid Nanoparticles CDMO Market report projects double-digit growth by 2027, highlighting key players including Evonik Health Care, Merck, and CordenPharma.


ACS Publication: Published new research on transition temperature-guided design of lipid nanoparticles for enhanced mRNA delivery.


Nature Publication: Published research on liposomal lipid nanoparticles for extrahepatic delivery of mRNA, showing longer circulation lifetimes and enhanced transfection properties.


Upcoming Industry Event: Innovations in pDNA, mRNA, and LNP Development and Manufacturing event scheduled for May 12, 2025.


Detailed News Summaries

Mana.bio

Mana.bio, a seed-stage biotech company, presented data on their novel AI-driven safety model for improving lipid nanoparticle tolerability. Their approach leverages artificial intelligence to enhance the development of RNA-based medicines.

Release Date: May 7, 2025


Grit Biotechnology

Grit Biotechnology presented multiple scientific breakthroughs at the ASGCT 2025 Annual Meeting, including their work on enhancing production and functional potential of tumor-infiltrating lymphocytes via lipid nanoparticle-mediated CRISPR/Cas9 gene editing. The company is pioneering next-generation immunotherapies and precision delivery technologies through a strategic collaboration with Vitalgen.Release Date: May 12, 2025


Generation Bio

Generation Bio reported business highlights including the advancement of their cell-targeted lipid nanoparticle (ctLNP) technology for siRNA delivery. The company plans to announce their lead target and portfolio strategy by mid-2025.

Release Date: May 7, 2025


Aera Therapeutics

Aera Therapeutics, founded by CRISPR pioneer Feng Zhang, has shifted its focus to lipid nanoparticles for T-cell targeting therapy while continuing development of their protein nanoparticle platform. This strategic pivot aims to jumpstart the company's therapeutic pipeline.

Release Date: May 2, 2025


Serina Therapeutics

Serina Therapeutics secured $15 million in equity financing including a $5 million private placement in April 2025. The company presented data at the 4th LNP Formulation & Process Development Summit 2025 demonstrating that their POZ-lipid, a key component of lipid nanoparticles, did not trigger an IgM or IgG antibody response following repeat dosing in rats, unlike polyethylene glycol (PEG)-lipid standards commonly used in current LNP formulations.

Release Date: May 9, 2025

Location: Huntsville, USA


Acuitas Therapeutics

Acuitas Therapeutics shared key findings from their latest mRNA-LNP therapeutic research during the 2025 World Vaccine Congress. The company presented data on ALC-0315 (the ionizable lipid used in COMIRNATY®) and its application in mRNA cancer immunotherapy, as well as novel lipids with improved virus-specific immunogenicity for prophylactic vaccine development.

Release Date: May 9, 2025

Location: Vancouver, BC, Canada


Acuitas Therapeutics

Acuitas Therapeutics announced they will present new data at ASGCT 2025 showing successful repeated dosing of an mRNA-LNP in monkeys, as well as advancements in LNP delivery beyond the liver, including expanded potential for innovative therapeutic modalities such as CAR T-cell therapies.

Location: Vancouver, BC, Canada


Various Pharmaceutical Companies

A new market report indicates the Global Lipid Nanoparticles CDMO Market is expected to witness healthy double-digit growth by 2027. The report notes that globally, more than 2,000 LNP-related pipeline drugs are in development. Key players in the market include Evonik Health Care, Merck, CordenPharma, Phosphorex, eTheRNA Manufacturing, Fujifilm Pharmaceuticals, Helix Biotech, BIOVECTRA, and Vernal Biosciences.

Release Date: May 9, 2025


ACS Publication


Transition Temperature-Guided Design of Lipid Nanoparticles for Effective mRNA Delivery
Transition Temperature-Guided Design of Lipid Nanoparticles for Effective mRNA Delivery

Researchers published a study in ACS describing the synthesis of a new series of ionizable lipids with tailored properties to enhance the delivery of mRNA. The research focuses on using transition temperature characteristics to guide the design of more effective lipid nanoparticles.

Release Date: May 5, 2025

Authors: Jeong Eun Shin, Eun-jeong Won, Junchao Xu et al.


Nature Publication


LNP mRNA systems were formulated as described in Methods containing NanoLuc mRNA (808 nt; N/P = 6) with lipid compositions nor-MC3/ ESM: cholesterol/ PEG-DMG at varying ratios of bilayer lipid (ESM and equimolar cholesterol) to ionizable lipid (RB/I). These formulations correspond to RB/I of 9, 4, 2.3, 1.5, 1, 0.67 and 0.43. The Onpattro-like formulation consists of MC3/DSPC/cholesterol/PEG-DMG (50/10/38.5/1.5 mol/mol). If it is assumed that the cholesterol and DSPC reside exclusively in the monolayer or bilayer environments, the RB/I for this formulation is 1.03. A Lipids in ethanol are mixed with mRNA in 25 mM NaOAc (pH 4) to give rise to LNP mRNA systems that are either liposomal LNP systems or solid core systems where at least part of the exterior surface consists of a lipid monolayer. B Encapsulation efficiencies of LNP NanoLuc mRNA systems with varying RB/I values (mean ± S.D., n = 3). C Hydrodynamic diameter (DLS measurement, number mean) for various RB/I ratios (mean ± S.D., n = 3). D The classification of LNP morphologies within the formulated population. LNP morphology was defined by its oil core or lamellar/multilamellar liposomal features as determined from cryo-TEM micrographs. E Cryo-TEM micrographs of LNP mRNA systems prepared using various RB/I values, micrograph has been reproduced twice. F Luminescence of Huh7 cells incubated for 24 h with LNP NanoLuc mRNA systems (0.1–1 μg mRNA/mL), decrease in RB/I indicated from beige to dark red, with Onpattro-like formulation (indicated as gray) over a range of RB/I values (mean ± S.E.M., n = 6). Source data are provided as a Source Data file. Figure 1A was partially created in BioRender. Cheng, M. (2025) https://BioRender.com/o07c413. All LNP illustrations are original and were created using Inkscape.
LNP mRNA systems were formulated as described in Methods containing NanoLuc mRNA (808 nt; N/P = 6) with lipid compositions nor-MC3/ ESM: cholesterol/ PEG-DMG at varying ratios of bilayer lipid (ESM and equimolar cholesterol) to ionizable lipid (RB/I). These formulations correspond to RB/I of 9, 4, 2.3, 1.5, 1, 0.67 and 0.43. The Onpattro-like formulation consists of MC3/DSPC/cholesterol/PEG-DMG (50/10/38.5/1.5 mol/mol). If it is assumed that the cholesterol and DSPC reside exclusively in the monolayer or bilayer environments, the RB/I for this formulation is 1.03. A Lipids in ethanol are mixed with mRNA in 25 mM NaOAc (pH 4) to give rise to LNP mRNA systems that are either liposomal LNP systems or solid core systems where at least part of the exterior surface consists of a lipid monolayer. B Encapsulation efficiencies of LNP NanoLuc mRNA systems with varying RB/I values (mean ± S.D., n = 3). C Hydrodynamic diameter (DLS measurement, number mean) for various RB/I ratios (mean ± S.D., n = 3). D The classification of LNP morphologies within the formulated population. LNP morphology was defined by its oil core or lamellar/multilamellar liposomal features as determined from cryo-TEM micrographs. E Cryo-TEM micrographs of LNP mRNA systems prepared using various RB/I values, micrograph has been reproduced twice. F Luminescence of Huh7 cells incubated for 24 h with LNP NanoLuc mRNA systems (0.1–1 μg mRNA/mL), decrease in RB/I indicated from beige to dark red, with Onpattro-like formulation (indicated as gray) over a range of RB/I values (mean ± S.E.M., n = 6). Source data are provided as a Source Data file. Figure 1A was partially created in BioRender. Cheng, M. (2025) https://BioRender.com/o07c413. All LNP illustrations are original and were created using Inkscape.

Researchers published a paper in Nature investigating the properties of LNP mRNA systems containing high proportions of bilayer-forming lipids, using equimolar egg sphingomyelin and cholesterol. They demonstrated that liposomal LNPs exhibit longer circulation lifetimes than standard LNP systems and have enhanced extrahepatic transfection properties.

Release Date: May 3, 2025

Authors: Miffy Hok, Yan Cheng et al.



Upcoming Industry Event

An industry event focusing on innovations in pDNA, mRNA, and LNP development and manufacturing is scheduled for May 12, 2025, offering expert perspectives and networking opportunities for professionals in the field.

Release Date: May 12, 2025


bottom of page